Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunocore Holdings plc - American Depositary Shares (NQ:IMCR)

33.02 -0.73 (-2.18%)
Streaming Delayed Price Updated: 11:30 AM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunocore Holdings plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
3 Fast-Growing Stocks Analysts See Doubling in Price
Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches. 
Via MarketBeat
News headline image
Navigating 8 Analyst Ratings For Immunocore Hldgs ↗
 
Via Benzinga
News headline image
A Closer Look at 9 Analyst Recommendations For Immunocore Hldgs ↗
 
Via Benzinga
News headline image
Analyst Ratings For Immunocore Hldgs ↗
 
Via Benzinga
News headline image
Analyst Expectations For Immunocore Hldgs's Future ↗
 
Via Benzinga
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore reports third quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
The Latest Analyst Ratings For Immunocore Hldgs ↗
 
Via Benzinga
News headline image
Deep Dive Into Immunocore Hldgs Stock: Analyst Perspectives (9 Ratings) ↗
 
Via Benzinga
News headline image
Immunocore to present at the 2024 Cantor Global Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore announces transition of Chief Financial Officer
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore reports second quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
3 Small-Cap Stocks with Significant Growth Potential ↗
As sector rotation continues, it could be time for investors to consider these small-cap growth stocks that institutions love. 
Via InvestorPlace
News headline image
Peeling Back The Layers: Exploring Immunocore Hldgs Through Analyst Insights ↗
 
Via Benzinga
News headline image
Analyst Expectations For Immunocore Hldgs's Future ↗
 
Via Benzinga
News headline image
Where Immunocore Hldgs Stands With Analysts ↗
 
Via Benzinga
News headline image
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to present at the Jefferies Global Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
IMCR Stock Earnings: Immunocore Hldgs Misses EPS, Misses Revenue for Q1 2024 ↗
IMCR stock results show that Immunocore Hldgs missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Immunocore reports first quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.